The impact of high versus standard enteral protein provision on functional recovery following intensive care admission (PRECISE trial): study protocol for a randomized controlled, quadruple blinded, multicenter, parallel group trial in mechanically ventilated patients.
Critical illness
Dietary protein
Enteral nutrition
Functional outcomes
Nutrition therapy
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
19 Jun 2023
19 Jun 2023
Historique:
received:
24
03
2023
accepted:
16
05
2023
medline:
21
6
2023
pubmed:
20
6
2023
entrez:
19
6
2023
Statut:
epublish
Résumé
Critically ill patients are subject to severe skeletal muscle wasting during intensive care unit (ICU) stay, resulting in impaired short- and long-term functional outcomes and health-related quality of life. Increased protein provision may improve functional outcomes in ICU patients by attenuating skeletal muscle breakdown. Supporting evidence is limited however and results in great variety in recommended protein targets. The PRECISe trial is an investigator-initiated, bi-national, multi-center, quadruple-blinded randomized controlled trial with a parallel group design. In 935 patients, we will compare provision of isocaloric enteral nutrition with either a standard or high protein content, providing 1.3 or 2.0 g of protein/kg/day, respectively, when fed on target. All unplanned ICU admissions with initiation of invasive mechanical ventilation within 24 h of admission and an expected stay on ventilator support of at least 3 days are eligible. The study is designed to assess the effect of the intervention on functional recovery at 1, 3, and 6 months following ICU admission, including health-related quality of life, measures of muscle strength, physical function, and mental health. The primary endpoint of the trial is health-related quality of life as measured by the Euro-QoL-5D-5-level questionnaire Health Utility Score. Overall between-group differences will be assessed over the three time points using linear mixed-effects models. The PRECISe trial will evaluate the effect of protein on functional recovery including both patient-centered and muscle-related outcomes. ClinicalTrials.gov Identifier: NCT04633421 . Registered on November 18, 2020. First patient in (FPI) on November 19, 2020. Expected last patient last visit (LPLV) in October 2023.
Sections du résumé
BACKGROUND
BACKGROUND
Critically ill patients are subject to severe skeletal muscle wasting during intensive care unit (ICU) stay, resulting in impaired short- and long-term functional outcomes and health-related quality of life. Increased protein provision may improve functional outcomes in ICU patients by attenuating skeletal muscle breakdown. Supporting evidence is limited however and results in great variety in recommended protein targets.
METHODS
METHODS
The PRECISe trial is an investigator-initiated, bi-national, multi-center, quadruple-blinded randomized controlled trial with a parallel group design. In 935 patients, we will compare provision of isocaloric enteral nutrition with either a standard or high protein content, providing 1.3 or 2.0 g of protein/kg/day, respectively, when fed on target. All unplanned ICU admissions with initiation of invasive mechanical ventilation within 24 h of admission and an expected stay on ventilator support of at least 3 days are eligible. The study is designed to assess the effect of the intervention on functional recovery at 1, 3, and 6 months following ICU admission, including health-related quality of life, measures of muscle strength, physical function, and mental health. The primary endpoint of the trial is health-related quality of life as measured by the Euro-QoL-5D-5-level questionnaire Health Utility Score. Overall between-group differences will be assessed over the three time points using linear mixed-effects models.
DISCUSSION
CONCLUSIONS
The PRECISe trial will evaluate the effect of protein on functional recovery including both patient-centered and muscle-related outcomes.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov Identifier: NCT04633421 . Registered on November 18, 2020. First patient in (FPI) on November 19, 2020. Expected last patient last visit (LPLV) in October 2023.
Identifiants
pubmed: 37337234
doi: 10.1186/s13063-023-07380-3
pii: 10.1186/s13063-023-07380-3
pmc: PMC10280915
doi:
Banques de données
ClinicalTrials.gov
['NCT04633421']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
416Informations de copyright
© 2023. The Author(s).
Références
Intensive Care Med. 2017 Nov;43(11):1637-1647
pubmed: 28936712
BMJ. 2009 Oct 16;339:b3723
pubmed: 19837741
N Engl J Med. 2023 Mar 9;388(10):913-924
pubmed: 36884324
Am J Respir Crit Care Med. 2017 Nov 1;196(9):1122-1130
pubmed: 28537429
Intensive Care Med. 2017 Sep;43(9):1270-1281
pubmed: 28289812
N Engl J Med. 2011 Aug 11;365(6):506-17
pubmed: 21714640
Am J Respir Crit Care Med. 2016 Oct 1;194(7):831-844
pubmed: 26974173
Lancet. 2019 Jun 8;393(10188):2312-2321
pubmed: 31030981
J Psychosom Res. 1997 Jan;42(1):17-41
pubmed: 9055211
Acta Anaesthesiol Scand. 2018 Apr;62(4):531-539
pubmed: 29315454
Clin Nutr. 2019 Feb;38(1):48-79
pubmed: 30348463
J Crit Care. 2016 Jun;33:137-44
pubmed: 26948254
Curr Opin Crit Care. 2018 Oct;24(5):428-433
pubmed: 30074502
Crit Care. 2016 Nov 10;20(1):367
pubmed: 27832823
JAMA. 2013 Jan 16;309(3):249-56
pubmed: 23321763
Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):221-33
pubmed: 24625040
Curr Opin Clin Nutr Metab Care. 2020 Mar;23(2):96-101
pubmed: 31904602
JPEN J Parenter Enteral Nutr. 2022 Jan;46(1):12-41
pubmed: 34784064
Contemp Clin Trials Commun. 2018 Mar 28;10:80-85
pubmed: 29696162
Sci Data. 2016 Mar 15;3:160018
pubmed: 26978244
Pharmacoecon Open. 2022 Nov;6(6):823-836
pubmed: 35927410
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Age Ageing. 2020 Oct 23;49(6):1071-1079
pubmed: 32392289
Value Health. 2017 Apr;20(4):644-650
pubmed: 28408007
N Engl J Med. 2018 Nov 08;379(19):1823-1834
pubmed: 30346225
JPEN J Parenter Enteral Nutr. 2016 Aug;40(6):795-805
pubmed: 26635305
Am J Respir Crit Care Med. 2014 Aug 15;190(4):410-20
pubmed: 24825371
Crit Care. 2019 Jan 14;23(1):12
pubmed: 30642377
N Engl J Med. 2011 Apr 7;364(14):1293-304
pubmed: 21470008
Lancet. 2018 Jan 13;391(10116):133-143
pubmed: 29128300
Am J Respir Crit Care Med. 2020 Apr 1;201(7):814-822
pubmed: 31904995
JAMA. 2013 May 22;309(20):2130-8
pubmed: 23689848
J Orthop Sports Phys Ther. 2018 Sep;48(9):685-693
pubmed: 29792107
Crit Care. 2015 Aug 05;19:274
pubmed: 26242743
PLoS One. 2015 Nov 10;10(11):e0141582
pubmed: 26556791
JPEN J Parenter Enteral Nutr. 2020 May;44(4):610-620
pubmed: 31617220
Clin Nutr. 2019 Apr;38(2):883-890
pubmed: 29486907
Am J Respir Crit Care Med. 2012 Aug 15;186(4):302-4
pubmed: 22896591
Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1384-7
pubmed: 9817683
JPEN J Parenter Enteral Nutr. 2009 May-Jun;33(3):277-316
pubmed: 19398613
Intensive Care Med. 2011 Apr;37(4):601-9
pubmed: 21340655
JAMA. 2018 Oct 2;320(13):1328-1337
pubmed: 30285177
Crit Care Med. 2011 Aug;39(8):1929-34
pubmed: 21572324
JAMA. 2013 Oct 16;310(15):1591-600
pubmed: 24108501
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Intensive Care Med. 2017 Sep;43(9):1239-1256
pubmed: 28374096
Lancet. 2023 Feb 18;401(10376):568-576
pubmed: 36708732
Value Health. 2016 Jun;19(4):343-52
pubmed: 27325326
JPEN J Parenter Enteral Nutr. 2021 May;45(4):699-709
pubmed: 33296079
BMJ. 2013 Mar 19;346:f1532
pubmed: 23512759
N Engl J Med. 2015 Jun 18;372(25):2398-408
pubmed: 25992505